Clinical practice guideline for activated phosphatidyl inositol 3-kinase-delta syndrome in Japan
Open Access
- 13 May 2023
- journal article
- review article
- Published by Taylor & Francis in Immunological Medicine
- Vol. 46 (4) , 153-157
Abstract
Activated phosphatidyl inositol 3-kinase-delta syndrome (APDS) due to gain-of-function variant in the class IA PI3K catalytic subunit p110δ (responsible gene: PIK3CD) was described in 2013. The disease is characterized by recurrent airway infections and bronchiectasis. It is associated with hyper-IgM syndrome due to the defect of immunoglobulin class switch recombination and decreased CD27-positive memory B cells. Patients also suffered from immune dysregulations, such as lymphadenopathy, autoimmune cytopenia or enteropathy. T-cell dysfunction due to increased senescence is associated with a decrease in CD4-positive T lymphocytes and CD45RA-positive naive T lymphocytes, along with increased susceptibility to Epstein-Barr virus/cytomegalovirus infections. In 2014, loss-of-function (LOF) mutation of p85α (responsible gene: PIK3R1), a regulatory subunit of p110δ, was identified as a causative gene, followed in 2016 by the identification of the LOF mutation of PTEN, which dephosphorylates PIP3, leading to the differentiation of APDS1 (PIK3CD-GOF), APDS2 (PIK3R1-LOF) and APDS-L (PTEN-LOF). Since the pathophysiology of patients with APDS varies with a wide range of severity, it is crucial that patients receive appropriate treatment and management. Our research group created a disease outline and a diagnostic flow chart and summarized clinical information such as the severity classification of APDS and treatment options.Keywords
Funding Information
- Ministry of Health, Labor and Welfare (20FC1053)
- Japan Agency for Medical Research and Development (JP21lk0201150, JP21bm0804004, JP19bm0804001)
This publication has 17 references indexed in Scilit:
- Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisibBlood, 2017
- Hematopoietic stem cell transplant in patients with activated PI3K delta syndromeJournal of Allergy and Clinical Immunology, 2017
- Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort studyJournal of Allergy and Clinical Immunology, 2017
- Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome–like immunodeficiencyJournal of Allergy and Clinical Immunology, 2016
- Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort studyJournal of Allergy and Clinical Immunology, 2016
- Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3KJournal of Experimental Medicine, 2014
- A human immunodeficiency caused by mutations in the PIK3R1 geneJournal of Clinical Investigation, 2014
- Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway DamageScience, 2013
- Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiencyNature Immunology, 2013
- PI3K in lymphocyte development, differentiation and activationNature Reviews Immunology, 2003